S-adenosylmethionine (SAMe) modulates interleukin-10 and interleukin-6, but not TNF, production via the adenosine (A2) receptor.
S-adenosylmethionine (SAMe) is the first product in methionine metabolism and serves as a precursor for glutathione (GSH) as well as a methyl donor in most transmethylation reactions. The administration of exogenous SAMe has beneficial effects in many types of liver diseases. One mechanism for the hepatoprotective action is its ability to regulate the immune system by modulating cytokine production from LPS stimulated monocytes. In the present study, we investigated possible mechanism(s) by which exogenous SAMe supplementation modulated production of TNF, IL-10 and IL-6 in LPS stimulated RAW 264.7 cells, a murine monocyte cell line. Our results demonstrated that exogenous SAMe supplementation inhibited TNF production but enhanced both IL-10 and IL-6 production. SAMe increased intracellular GSH level, however, N-acetylcysteine (NAC), the GSH pro-drug, decreased the production of all three cytokines. Importantly, SAMe increased intracellular adenosine levels, and exogenous adenosine supplementation had effects similar to SAMe on TNF, IL-10 and IL-6 production. 3-Deaza-adenosine (DZA), a specific inhibitor of S-adenosylhomocysteine (SAH) hydrolase, blocked the elevation of IL-10 and IL-6 production induced by SAMe, which was rescued by the addition of exogenous adenosine. Furthermore, the enhancement of LPS-stimulated IL-10 and IL-6 production by both SAMe and adenosine was inhibited by ZM241385, a specific antagonist of the adenosine (A(2)) receptor. Our results suggest that increased adenosine levels with subsequent binding to the A(2) receptor account, at least in part, for SAMe modulation of IL-10 and IL-6, but not TNF production, from LPS stimulated monocytes.
Song
Zhenyuan
Z
Department of Medicine, University of Louisville College of Medicine, Louisville, KY 40292, USA.
Uriarte
Silvia
S
Sahoo
Rashmita
R
Chen
Theresa
T
Barve
Shirish
S
Hill
Daniell
D
McClain
Craig
C
D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism; D000229:Dependovirus; D005978:Glutathione / Q000378:metabolism; D016753:Interleukin-10 / Q000096:biosynthesis / Q000378:metabolism; D015850:Interleukin-6 / Q000096:biosynthesis / Q000378:metabolism; D008070:Lipopolysaccharides; D051379:Mice; D043683:Receptors, Adenosine A2 / Q000187:drug effects* / Q000378:metabolism; D012436:S-Adenosylmethionine / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D058917:Adenosine A2 Receptor Antagonists; D015850:Interleukin-6; D008070:Lipopolysaccharides; D043683:Receptors, Adenosine A2; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D012436:S-Adenosylmethionine; D000242:Cyclic AMP; D005978:Glutathione